CSI Market
Sign In | Register

Collegium Pharmaceutical Inc (COLL) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access COLL quarterly Cash Flow →
This cash flow overview for Collegium Pharmaceutical Inc spans from Dec 31 2021 to Dec 31 2025, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income62.87
Depreciation & amortization4.18
Amortization of Other Assets227.23
Increase (Decrease) in Deferred Revenue0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability-1.18
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-5.35
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation41.91
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt15.99
Amortization Of Incentive From Lessor-
Increase Decrease In Accrued Rebates Returns And Discounts2.85
Amortization And Impairment Of Intangible Assets-
Cost Of Goods And Services Sold Amortization-
Operating Lease Payments Non Cash0.34
Net Accretion For Deferred Royalty Obligation0.95
Income taxes-25.66
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable17.20
Increase (Decrease) in Accounts Payable6.72
Increase (Decrease) in Accrued Liabilities-9.50
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-7.97
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.27
Discontinued operations0.00
Net Cash flow from Operating Activities329.32
Investing Activities
Capital Expenditures-1.74
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities65.18
Payments to Acquire Marketable Securities-126.97
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-63.53
Financing Activities
Short-term debt Net565.18
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-635.56
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-19.46
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Increase (Decrease) in Deposits Outstanding0.00
Other financing activities net0.00
Other net-137.92
Sale Of Stock Consideration Received On Transaction-
Issuance Costs From Issuance Of Common Stock-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents96.61
Restricted Cash And Cash Equivalents Noncurrent20.91
Proceeds From Term Note Modification-
Repurchase Of Convertible Notes Including Premium And Fees-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-110.25
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow327.58
Total Cash Flow155.55
4 historic quarters locked

Sign in to unlock the full Collegium Pharmaceutical Inc cash flow history.

Sign In Create Free Account

About Collegium Pharmaceutical Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: coll-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-011992

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License